Tertiary lymphoid structures (TLS) often develop at sites of persistent inflammation, including cancers and autoimmune diseases. In most cases, the presence of TLS correlates with active immune responses. Because of their proximity to pathological loci, TLS are an intriguing target for the manipulation of immune responses. For several years, it has become clear that lymphotoxin (LT) signalling plays critical roles in lymphoid tissue organogenesis and maintenance. In the current review, we will discuss the role of LT signalling in the development of TLS. With a focus on cancers and autoimmune diseases, we will highlight the correlations between TLS and disease progression. We will also discuss the current efforts and potential directions for manipulating TLS for immunotherapies.
INTRODUCTION
Inflammation is the immune response to various pathological conditions, such as cancer, autoimmune disease and infection. 1 Inflammatory mediators, especially cytokines, chemokines and adhesion molecules, recruit and activate various types of innate and adaptive immune cells to the site of inflammation, including macrophages, DCs, mast cells as well as T and B cells. 2 In the case of persistent inflammation, the migration and positioning of immune cells usually follow certain patterns, which are similar to those observed in the secondary lymphoid organs (SLO). These structures have been named tertiary lymphoid structure (TLS; also called tertiary lymphoid organs (TLO)). 3, 4 Several cytokines/chemokines and their corresponding receptors have been shown to be involved in the formation of TLS, including lymphotoxins (LTs), tumour necrosis factor (TNF), CCL21, CCL19, CXCL13 and others. Among them, the LT signalling pathway plays key roles. 5, 6 In this review, we will highlight the role of LT signalling in the formation of TLS and its application for drug design targeting cancers and autoimmune diseases.
LYMPHOTOXIN SIGNALING: AN OVERVIEW LTs belong to the TNF superfamily. Two distinct forms of LTs, LTα and LTβ, have been identified. They show different expression patterns and cellular distributions. LTα was originally identified because of its ability to induce tumour cell death in vitro; thus, it was named TNFβ. 7, 8 Similar to TNF, LTα itself can form a homotrimer that binds to TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2; Figure 1 ). 9 LTα can also form heterodimers together with LTβ as either LTα2β1 or LTα1β2. Among them, LTα1β2 is the predominant form. LTα1β2 binds to lymphotoxin beta receptor (LTβR). 10 LTβR is broadly expressed by stromal cells in lymphoid tissues, epithelial cells, monocytes, DCs and other cell types (Table 1) . 11, 12 LTβR can bind to another TNF superfamily member, LIGHT, which is homologous to lymphotoxins. It has inducible expression and competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed on T lymphocytes. LIGHT can also provide co-stimulatory signals to T cells by interacting with HVEM. 13 Together, these cytokines and receptors form a complex signalling network that plays important roles in several immunological processes. from genetically manipulated mice. [14] [15] [16] [17] Mice deficient in LTα show significant defects in lymphoid organ development. Specifically, these mice are born without secondary lymphoid organs, including lymph nodes (LNs) and Payer's Patches (PPs; Table 1 ). LTβ-deficient mice phenocopy what has been observed in LTα mice. 18, 19 Interestingly, although TNF-and TNFR-deficient mice lack PPs, they still have normal LN. 17, [20] [21] [22] These data indicate a more profound role of LTβR signalling in lymphoid tissue organogenesis and maintenance.
LTβR regulates mesenchymal stromal cells for immune cell clustering and patterning A well-defined role of LTβR signalling during SLO development is its ability to induce the expression of lymphoid chemokines and adhesion molecules for initial immune cell clustering. For lymph node/PP development, LTβR signalling triggered by LT from lymphoid tissue inducer (LTi) cells induces the expression of many chemokines and adhesion molecules, including CCL19, CCL21, CXCL12, CXCL13, ICAM1, VCAM1 and MAdCAM1. 23 These molecules coordinate a positive feedback loop by recruiting more LTi cells. They also recruit other immune cells such as B and T cells for further lymphoid tissue maturation and organization. This function of LTβR is true not only in LN/PP development but also in nonlymphoid tissues. In fact, the exogenous expression of LT or LIGHT, which activates LTβR signalling, is able to promote functional lymphoid neogenesis in non-lymphoid tissues. [24] [25] [26] The essential role of LTβR signalling in mesenchymal cells for TLS has also been reported. [27] [28] [29] In these studies, an arterial TLS model in apoE − / − mice was examined. When LTβR was conditionally deleted from vascular smooth muscle cells, although aorta tertiary lymphoid organ (ATLO) neogenesis was not affected, aberrant ATLO structures, as indicated by reduced size, loose T-and B-cell infiltrates and segregation, were found.
LTβR regulates mesenchymal stromal cell differentiation Fibroblastic reticular cells (FRCs) and follicular dendritic cells (FDCs) are important organizer stromal cells in T and B zones, respectively. During SLO development, FDCs and FRCs are differentiated from mesenchymal precursors. LTβR signalling was recently found to be important for their differentiation. LN FRCs are mainly derived from adipocyte precursors, and their differentiation is critically dependent on the LTβR-NFκB2-RelB signalling pathway. 30 Furthermore, in vivo organogenesis assays showed that embryonic and adult adipocyte precursor cells can migrate into newborn lymph nodes and differentiate into a variety of lymph node stromal cells. FDCs can also arise from ubiquitous perivascular precursors (preFDCs) expressing platelet-derived growth factor receptor β (PDGFRβ). The expansion of preFDCs requires both LTi cells and lymphotoxin. 31 The ubiquity of preFDCs and their strategic location at blood vessels may explain the de novo generation of organized TLS at sites of lymphocytic inflammation. Whether a similar LTβR-dependent mechanism controls TLS development remains to be determined.
LTα3 LIGHT LIGHT TNF Figure 1 The lymphotoxin signalling network. TNF and LTα3 can bind to TNFRI and TNFRII. Both LTα1β2 and LIGHT bind to LTβR. LIGHT can also interact with HVEM and deliver co-stimulatory signals to T cells. TNF and LIGHT can be either membrane-bound or soluble. TNF, tumour necrosis factor; LT, lymphotoxin; TNFRI, TNF receptor I; TNFRII, TNF receptor II; LTβR, lymphotoxin beta receptor; HVEM, herpesvirus entry mediator; LIGHT, homologous to lymphotoxins, inducible expression, competes with herpes simplex virus glycoprotein for HVEM, a receptor expressed on T lymphocytes. 
LTβR regulates HEV for organized lymphocyte recruitment
The LTβR signalling pathway plays critical roles for high endothelial venule (HEV) differentiation and function. 32, 33 HEVs are specialized blood vessels that are essential for the migration of lymphocytes into SLO. 34 Compared to capillaries, HEVs are distinct in their expression of peripheral node addressins (PNADs). PNADs are a group of highly glycosylated and sulphated forms of sialomucins, such as glycosylationdependent cell-adhesion molecule-1 (GlyCAM-1), CD34, podocalyxin, endoglycan and endomucin. 35, 36 Some sialomucins are also expressed in capillaries, though with lower levels of post-translational modifications. This may be due to the preferential expression of genes involved in glycoconjugate formation in HEVs. 36 Besides PNADs, HEVs also express high levels of lymphoid chemokines, such as CCL21. 37 DCs promote LT signalling through LTβR for HEV differentiation and function. 38 In addition, LTβR signalling is also involved in HEV network growth via regulating VEGF expression. FRCs are the major source of VEGF in lymph nodes. 39 LTβR signalling in FRCs is important for VEGF production. 40 Alternatively, DCs have also been reported to express VEGF directly for initial HEV formation. 40, 41 HEV-like structures are also found in TLS. Because of the similarity between SLO and TLS, it is speculated that LT signalling is also involved in HEV differentiation and function in TLSs. In line with this notion, HEV-like structures are associated with LT-expressing DCs in human breast cancer. 42 However, the exact roles of DC and LT signalling on HEV differentiation, growth and function in TLSs remain to be determined.
Different lymphoid tissue inducers for SLO and TLS
In addition to stromal cells and endothelial cells, LTi cells are also critical for LN development, as they deliver the initial triggering of stromal cells. For SLO development, the crucial role of CD4 + CD3 − RORγt + LTi cells has been well documented. [43] [44] [45] Whether LTi cells play a role in TLS development remains controversial. In a model where TLS was induced by ectopic expression of CCL21 in the thyroid gland, the formation of TLS was independent of LTi cells. 46 However, in another study, IL-7 overexpression led to the formation of multiple organized ectopic lymph nodes and caecal patches because of the increased survival of LTi cells. 47 Mice overexpressing IL-7 but lacking either RORγ, a factor required for LTi cell generation, or LT had no ectopic lymph nodes. Even so, the data do not exclude the role of Th17 in TLS development, since RORγt is also required for Th17 differentiation. In fact, several studies have linked IL-17 and Th17 to the development of TLSs in various models. [48] [49] [50] In addition, B cells have also been reported to be involved in TLS formation in RA patients. 51 Recently, an intriguing study showed that B cells can serve as LTi cells by providing LT signalling for microbiota-induced tertiary lymphoid tissue formation, even in RORγt-deficient mice, which lack both LTi cells and Th17 cells. 52 Therefore, different LT-producing cells may work as LTi cells depending on the scenarios. For TLS development in cancers, the LT inducer cells have not been reported. Since LTexpressing DCs have been shown to be associated with TLS, it may be an interesting candidate for testing.
TLS IN CANCER IMMUNOTHERAPY
Correlation between TLS and cancer progression: Clinical study TLSs form and attract lymphocytes during chronic inflammation. In the case of tumours, TLSs are formed adjacent to malignant cells. Compared to draining lymph nodes (dLNs), these structures are closer to tumour cells, which makes them better places for T cells to meet tumour antigen-carrying DCs and become primed. Clinically, the presence and abundance of TLSs in tumour patients usually correlate with active immune responses and better prognosis. 2, 53, 54 One piece of evidence comes from studies in melanoma. The distribution of DCs follows a certain pattern in melanoma tumour tissues. 55 Specifically, DC-Lamp + mature DCs are mostly confined to peritumoural areas, and a higher frequency of DC-Lamp + mature DCs correlates with better prognosis in patients. The presence of TLS in metastatic melanoma was further identified as lymphoid follicles containing HEVs and clusters of B cells, T cells, FDCs and mature DCs. 56 B cells inside these TLSs show signs of clonal amplification, somatic mutation and isotype switching, indicating active immune responses. Similar structures have also been confirmed by another group. 57 Furthermore, a 12-chemokine gene expression signature (GES) has been identified and can be used to predict the presence of TLSs. This 12-chemokine GES includes CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11 and CXCL13. Most of these cytokines have been shown to be critical for the formation of SLO and TLS. Interestingly, many of them can be directly upregulated by LT signalling. 58 In non-small cell lung cancer (NSCLC) patients, the existence of TLSs has been shown in tumours but not normal tissues. [59] [60] [61] These TLSs contained mature DC and T-cell clusters adjacent to B-cell follicles. The density of mature DCs is associated with favourable clinical outcomes. Intriguingly, the density of mature DCs also correlates with tumour infiltrating lymphocytes (TILs), which have been shown to correlate with better prognosis in many different cancers. 62 A follow-up study identified that tumour infiltrating T cells are predominantly of the effector-memory phenotype, which is consistent with the important role of TLSs as a site for T-cell priming. 63 Mature DCs are not the only cell type that correlates with the presence of TLS and better prognosis. In colorectal carcinoma patients, a higher number of CD3+ T-cell infiltration into tumour-associated lymphoid nodules predicts improved survival. [64] [65] [66] In a mouse model of colorectal cancer, the adoptive transfer of splenocytes results in the accumulation of lymphocytes at the TLS, suggesting an active role of TLSs in recruiting lymphocytes to tumour tissues. Higher TILs and the presence of TLSs also correlate with disease-free survival in patients with breast cancer 42,67-71 and melanoma. 55, 57, 64, 72 Taken together, these studies suggest a strong correlation between the presence of TLS and a better prognosis in cancer patients.
On the other hand, however, although the presence of TLS usually correlates with positive clinical outcome, it could also indicate an adverse prognosis in some scenarios. In breast cancer patients, a high number of tumour-infiltrating regulatory T (Ti-Treg) cells was found to be present in the peritumoural areas. 73 73 Targeting lymphotoxin signalling for cancer immunotherapy Tumour microenvironments are usually inhibitory and prevent effective lymphocyte priming. 74, 75 As TLSs are located adjacent to tumour cells, there could be several advantages to priming T cells inside TLSs. First, it is less difficult for antigenpresenting cells (APCs) to take up tumour antigens and migrate to TLSs. Second, the tumour antigen load in TLSs could be higher than tumour dLNs. 76 Third, activated effector cells can target tumour cells and stromal cells with less migration. 76, 77 In fact, bystander elimination of stromal cells is essential to control tumour growth. 78 Considering the significant correlation between the presence of TLSs and better prognosis, it has become an intriguing hypothesis that being able to induce TLS formation might also be a potent strategy to induce anti-tumour immunity (Figure 2) . 79 Several studies aiming at developing strategies to induce TLSs in order to enhance anti-tumour immune responses have been reported (Table 2) .
Because of its central role during lymphoid tissue neogenesis, LTβR has attracted the most attention. Early studies have shown that exogenous expression of LTβR ligands, either LT or LIGHT, is able to promote functional lymphoid neogenesis in non-lymphoid tissues. [24] [25] [26] In a proof-of-concept study, the expression of LTβR was evaluated using an immunohistologic survey. 81 Most samples (87% to 96%) showed at least 1 + staining for LTβR in human tumours. The wide expression of LTβR in tumour tissues lays the foundation for activating LTβR signalling for TLS induction. An agonistic antibody against LTβR has been developed. In both a human xenograft model and a mouse syngeneic model, the agonist anti-LTβR antibody is able to induce anti-tumour immune responses and increase lymphocyte infiltration into tumour tissues. 81 However, the anti-tumour effects were less impressive, possibly because of the wide expression of LTβR, which makes it hard to specifically activate LTβR signalling in tumour tissues. The lack of tumour-specific targeting also raised concerns regarding side effects. In fact, the systemic activation of LT signalling results in serous toxicity. 101 The other approach to activate LTβR signalling is through engagement with LIGHT. The expression of LIGHT in nonlymphoid tissues, such as islets, is able to induce development of TLS. 25 The ectopic activation of LTβR signalling induces diabetes as a result of autoimmune disease. This process can be blocked by a neutralizing recombinant LTβR fusion protein. Figure 2 Immune responses mediated by tumour-related tertiary lymphoid structures (TLSs). Lymphocytes are recruited from HEV to TLSs, where they form T-and B-cell-rich zones (1). Dendritic cells (DCs) take up antigens and present them to T cells (2) . After activation and proliferation, T cells can migrate to tumour cells for destruction (3) . Antigens can also be transferred to B cells to induce antibody production (4). Lymphotoxin signalling plays important roles in lymphocyte recruitment, stromal and LTi cell differentiation, and HEV organization. HEV, high endothelial venules. LTβR, lymphotoxin beta receptor.
Interestingly, forced expression of LIGHT in tumour cells promotes the formation of lymphoid-like structures for direct T-cell sequestration and activation, leading to tumour regression. 77, 84 Alternatively, mesenchymal stem cells engineered to express LIGHT can home into tumour tissues and promote anti-tumour immunity. 102 However, because of the wide expression of LIGHT receptors, a major challenge in the delivery of LT signalling for cancer immunotherapy is how to specifically target to the tumour (Table 1) . To overcome such a limitation, tumour-specific antibody targeting has been utilized to deliver LIGHT specifically to tumour tissues. 103 Further study suggested that LTβR signalling activated by LIGHT is able to attract lymphocytes to the tumour tissues, resulting in tumour destruction.
As a ligand of LTβR, LTα is another promising molecule for the activation of LTβR signalling. Several studies have been carried out with recombinant LTα that is fused to an anti-GD2 antibody for specific tumour targeting. 24, 80 This fusion protein is able to inhibit tumour growth and prolong survival in a syngeneic mouse melanoma model. Intriguingly, seven days after seven continually daily treatments with this fusion protein, HEV-like structures could already be observed inside tumours, supporting lymphocyte migration. 24 These studies suggest that the tumour-specific targeting of LT is able to induce the formation of TLSs in a short period of time and exert anti-tumour effects. 24 The strategies discussed above aim to activate LTβR signalling using either an agonist antibody or its ligands. On the other hand, another strategy is to deliver major effector molecules of LT signalling to tumour tissues, such as CCL21 or CCL19. CCL21 is a ligand of CCR7. It is an important effector chemokine that can mediate the homing of DCs and T cells to both lymphoid and non-lymphoid tissues. 104, 105 CCL21 overexpression in B16 melanoma results in tumour rejection. 106 Therapeutic application of CCL21 in tumour immunotherapy has also been reported. 107 Recombinant CCL21 is able to induce tumour regression. The anti-tumour effects were completely abolished in immunodeficient mice or in the absence of T cells, suggesting an essential role of adaptive immunity. Alternatively, cells transduced with CCL21 cDNA can be used instead of recombinant CCL21 protein. 108 Interestingly, intratumoral injection of DCs expressing CCL21 showed robust anti-tumour activity and induced regression in all tumours tested. In significant contrast, fibroblasts expressing the same chemokine can only induce regression in 25% of the mice. These results are consistent with the notion that DC is the major target of CCL21. 104 In another study, CCL21 was knocked down in a mouse melanoma model and an opposite result was observed. 109 Surprisingly, tumour cells expressing higher levels of CCL21 established an immunetolerant tumour microenvironment, which facilitates tumour progression. The tumour microenvironment in tumours expressing high levels of CCL21 was characterized by a ;higher number of Treg cells. This phenomenon is similar to what has been observed in some breast cancer patient samples, which also show a higher number of Treg in TLSs. 73 Considering the profound role of Treg cells during the progression of mouse melanoma, it is interesting to speculate that instead of promoting effector T-cell priming, TLS might facilitate the activation of Treg cells and inhibit effector T cells in tumours or tissues where Treg play a dominant role.
CCL19 and CCL21 share the same receptor, CCR7. Although they have a similar affinity to CCR7, the signalling induced by CCL19 and CCL21 is different. 110 Specifically, the binding of CCL19 to CCR7 induces internalization of the receptor, leading to desensitization. 111 Furthermore, binding CCL19 desensitized the receptor to subsequent responses to CCL21. Because of these reasons, it is likely that the anti-tumour effects of CCL19 in mouse tumour models are not as impressive as CCL21. [112] [113] [114] [115] Overall, CCL19 represents a more moderate, self-limited, and tuneable stimulator for CCR7 activation.
After induction, TLSs in tumour tissues are able to provoke anti-tumour immunity through several mechanisms that are quite unique compared to other therapeutic approaches. First, most current immunotherapies aim to activate/reactivate T cells inside tumours or dLNs. However, T cells inside established tumours are usually exhausted or anergic because of the inhibitory or prolonged activating microenvironment and are difficult to be activated. 116 In significant contrast, HEVs in TLSs support the recruitment of naive T cells from the periphery. 77, 117, 118 Naive T cells or newly attracted T cells are less exposed to the inhibitory microenvironment and have a lower threshold for activation. Second, the microenvironment in TLSs, including cytokines/chemokines and co-stimulatory signalling, promotes better priming of T cells and prevents them from reaching exhaustion or anergy. Third, as mentioned above, because of higher antigen loads and proximity to tumour cells, TLSs provide a better place for T cells to be primed and to infiltrate inside tumour tissues. Fourth, in situ T-cell priming can also lead to a broader and more comprehensive response, especially for antigens that are hard or unable to be crosspresented by APCs. In summary, the successful induction of TLSs in tumour tissues, either alone or combination with other therapies, may be a potent strategy for tumour immunotherapy.
TLS IN AUTOIMMUNE DISEASE
Role of TLS in autoimmune diseases TLS can be found in many autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and type 1 diabetes (T1D). However, unlike in tumours, the function and prognostic value of TLS in some autoimmune diseases are still controversial, depending on the disease and the loci of TLS formation.
In RA, it has long been observed that tissue-infiltrating lymphocytes can form ectopic follicles in some patients. 4 These follicles are organized in a way that is similar to SLO. 119, 120 LTβ and CXCL13 are characteristic cytokines/chemokines that can independently predict the presence of TLS in patients, which indicates a critical role of LT signalling during the formation of these follicles. 51 There is also a correlation between TLS and disease progression in RA. Specifically, FDCs in TLS express activation-induced cytidine deaminase (AID), an enzyme that is required for somatic hypermutation and the class-switch recombination of Ig genes. 121 B cells producing a specific marker of RA, anti-citrullinated protein/peptide antibodies, are found to be in close contact with FDCs. These data provide evidence that TLS in RA may support autoantibody production and contribute to disease progression. However, although the presence of TLS is associated with a higher level of lymphocyte infiltration and systemic inflammation, it does not seem to correlate with the severity of the disease. 122 A possible explanation is that clinical disease severity may be influenced by factors other than synovial inflammation.
Nephritis is the major cause of death for SLE. In the analysis of lupus nephritis biopsies, ectopic lymphoid structures were found to be associated with nephritis. 123 In those structures, T and B cells were well-organized together with FDCs. These samples were positive for many lymphoid chemokines that are negative in normal renal tissues, including CXCL12, BAFF, CXCL13, CCL21 and CXCL10. The presence of lymphoid structures is associated with in situ B-cell clonal expansion and somatic hypermutation. 123 These data suggested a correlation between TLS and disease progression. Similar patterns of TLS formation and chemokine expression were observed in a mouse model. 124 Furthermore, DCs in TLSs were shown to express a high level of type 1 interferon (IFN), which might be responsible for the pathogenesis of SLE.
Lymphotoxin signalling as a therapeutic target in autoimmune diseases
In many cases of autoimmune diseases, it is believed that TLSs play a positive role in disease progression, which is consistent with the notion that TLSs are a site of immune activation.
As LT signalling is critical for the development of TLS, many efforts have been focused on blocking this signalling as therapy for autoimmune diseases. 100, 125 An interesting example is the development of the anti-LTα antibody for the treatment of arthritis. Collagen-induced arthritis (CIA) is a commonly used murine autoimmune disease model in which the disease development depends on T helper (TH) cells. 126 In a survey of the gene expression profile in immune cells in CIA, the expression of LTα was found to be specifically in TH cells, especially TH1 and TH17 cells. 88 Treating CIA mice with an anti-LTα antibody significantly inhibited disease development. A mechanistic study showed that the administration of anti-LTα antibody depletes TH1 and TH17 cells, resulting in decreased IL-17, IFN-γ, and TNFα production. These data led to the development of the drug Pateclizumab, a humanized anti-LTα antibody. In clinical trials, Pateclizumab was used to treat RA and graft-versus-host disease (GVHD). 127, 128 Unfortunately, although proven to be safe in a phase 1 trial, it failed the phase 2 trial for RA because there were no significant benefits over placebo. 90 A possible explanation might be the tight regulation during TLS formation. 129 Although not successful in LTα blocking, probably because of less efficient blockade, blocking LT signalling with an effective LTβR-Ig 130 has been shown to reduce the formation of TLS and inhibit autoimmune disease progression in many different disease models, including T1D, Hashimoto's thyroiditis, and experimental autoimmune encephalomyelitis (EAE). [131] [132] [133] [134] The potent effects of LTβR-Ig in mouse models have pushed a humanized version, Baminercept, into clinical trials. 97 Its first clinical trial in RA was discontinued because no significant effect was observed. 135 However, further analysis showed that there were significant changes in some biomarkers and with clinical improvements in a subset of patients. 98 A second clinical trial against Sjogren's syndrome (SS) has also reached phase 2. Although there were no benefits for increasing salivary flow or reducing ocular dryness, Baminercept significantly improved the EULAR Sjogren's syndrome Disease Activity Index (ESSDAI). 99 CONCLUDING REMARKS Recent breakthroughs in immunotherapy have opened a new era of disease treatment. 136 Clinical trials with checkpoint blockade and chimeric antigen receptor-T-cell therapies have shown remarkable long-term efficacy in patients with a variety of cancers. [137] [138] [139] Although only a minority of the total treated patients respond to the current immunotherapy treatment, the unprecedented durable responses in some patients have shown that potent effects could be achieved with immunotherapies. Because of its close and active interactions with pathological tissues, TLS has become an intriguing target not only for studying disease progression but also for manipulating immune responses during immunotherapy. Studies during the past years have revealed a central role of LT signalling in the regulation of lymphoid neogenesis. With the manipulation of TLS development by increasing chemokines that attract more lymphocytes, the current durable effects with immunotherapy are expected to reach a broader range of patients soon.
